Treatment of lateral neck papillary thyroid carcinoma recurrence after selective lateral neck dissection.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 02 2018
revised: 02 04 2018
accepted: 07 04 2018
pubmed: 14 10 2018
medline: 15 10 2019
entrez: 14 10 2018
Statut: ppublish

Résumé

There is a paucity of data regarding optimal treatment options and outcomes for recurrent disease after lateral neck dissection in patients with papillary thyroid carcinoma. Retrospective review of patients who underwent either percutaneous ethanol injection or surgery for first-time ipsilateral recurrences after ipsilateral lateral neck dissection for papillary thyroid carcinoma was performed. Follow-up data were available for 54 patients with recurrences in 57 lateral necks treated by either percutaneous ethanol injection (n = 32) or surgery (n = 25). Tumor burden at the time of lateral neck recurrence differed between the groups including the largest lymph node diameter (mean: 13 mm vs 18 mm, P < .01) and the mean number of metastatic lymph nodes identified on ultrasound (1.3 vs 1.9, P = .04). Each modality alone achieved similar estimated rates of disease control at 36 months (75% for percutaneous ethanol injection and 74% for surgery, P = .8) with similar number of reinterventions (1.8 for percutaneous ethanol injection, 1.6 for surgery, P = .6). Both ethanol ablation and surgery can achieve disease control in the majority of patients with recurrences after ipsilateral lateral neck dissection for papillary thyroid carcinoma. Ethanol ablation, when used for treatment of a single small lymph node, can result in outcomes that are similar to reoperative surgery for larger and multiple lymph nodes.

Sections du résumé

BACKGROUND
There is a paucity of data regarding optimal treatment options and outcomes for recurrent disease after lateral neck dissection in patients with papillary thyroid carcinoma.
METHODS
Retrospective review of patients who underwent either percutaneous ethanol injection or surgery for first-time ipsilateral recurrences after ipsilateral lateral neck dissection for papillary thyroid carcinoma was performed.
RESULTS
Follow-up data were available for 54 patients with recurrences in 57 lateral necks treated by either percutaneous ethanol injection (n = 32) or surgery (n = 25). Tumor burden at the time of lateral neck recurrence differed between the groups including the largest lymph node diameter (mean: 13 mm vs 18 mm, P < .01) and the mean number of metastatic lymph nodes identified on ultrasound (1.3 vs 1.9, P = .04). Each modality alone achieved similar estimated rates of disease control at 36 months (75% for percutaneous ethanol injection and 74% for surgery, P = .8) with similar number of reinterventions (1.8 for percutaneous ethanol injection, 1.6 for surgery, P = .6).
CONCLUSIONS
Both ethanol ablation and surgery can achieve disease control in the majority of patients with recurrences after ipsilateral lateral neck dissection for papillary thyroid carcinoma. Ethanol ablation, when used for treatment of a single small lymph node, can result in outcomes that are similar to reoperative surgery for larger and multiple lymph nodes.

Identifiants

pubmed: 30314726
pii: S0039-6060(18)30503-8
doi: 10.1016/j.surg.2018.04.063
pii:
doi:

Substances chimiques

Solvents 0
Ethanol 3K9958V90M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-36

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Veljko Strajina (V)

Department of Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address: strajina.veljko@mayo.edu.

Benzon M Dy (BM)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Travis J McKenzie (TJ)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Zahraa Al-Hilli (Z)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Robert A Lee (RA)

Department of Radiology, Mayo Clinic, Rochester, Minnesota.

Mabel Ryder (M)

Division of Endocrinology, Metabolism, Nutrition & Diabetes, Mayo Clinic, Rochester, Minnesota.

David R Farley (DR)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Geoffrey B Thompson (GB)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Melanie L Lyden (ML)

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH